These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE; N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946 [TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial. Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799 [TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379 [TBL] [Abstract][Full Text] [Related]
5. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. Carrier M; Abou-Nassar K; Mallick R; Tagalakis V; Shivakumar S; Schattner A; Kuruvilla P; Hill D; Spadafora S; Marquis K; Trinkaus M; Tomiak A; Lee AYY; Gross PL; Lazo-Langner A; El-Maraghi R; Goss G; Le Gal G; Stewart D; Ramsay T; Rodger M; Witham D; Wells PS; N Engl J Med; 2019 Feb; 380(8):711-719. PubMed ID: 30511879 [TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P; N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113 [TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. Wang Y; Wang M; Ni Y; Liang Z Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870 [No Abstract] [Full Text] [Related]
11. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R; Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692 [TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308 [TBL] [Abstract][Full Text] [Related]
13. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902 [TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643 [TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD; Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756 [TBL] [Abstract][Full Text] [Related]
16. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR; Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789 [TBL] [Abstract][Full Text] [Related]